Table 2. Correlation of antigen... | American Society of Hematology

Table 2.

Correlation of antigen expression with clinical and biological variables

	HLA-DR	CD34	MPO	CD33	CD13	CDw65	CD117	CD14	CD2	CD4	CD5	CD7	CD10	CD19	TdT	CD41	CD56
Patients, N	177	177	177	177	177	177	177	177	142	177	130	177	177	177	177	99	42
Positive patients, n (%)	154 (87)	120 (68)	129 (73)	161 (91)	168 (95)	71 (40)	129 (73)	44 (25)	26 (18)	111 (63)	5 (4)	65 (37)	18 (10)	28 (16)	32 (18)	6 (6)	10 (24)
Age, y, Mean +/ mean −	54/62	54/56	53/58	54/60	55/43	53/58	58/61	53/54	58/54	55/54	ND	49/58	59/53	49/55^*	62/53^*	48/53	50/57
WBC at diagnosis, Mean +/ mean −	54/79	45/75^*	59/57	61/8^*	55/85	59/58	42/48	88/46^*	53/54	58/48	90/54	76/42^*	75/54	45/58	39/58	100/59	40/43
WHO PS, n (%)
<2	116 (87)	85 (64)	100 (75)	122 (92)	126 (95)	54 (41)	104 (78)^†	31 (23)	20 (18)	82 (62)	4 (4)	50 (38)	13 (10)	20 (15)	22 (16)	5 (7)	7 (22)
≥2	38 (86)	35 (79)	29 (66)	39 (89)	42 (95)	17 (39)	25 (57)^†	13 (29)	6 (19)	29 (66)	1 (3)	15 (34)	5 (11)	8 (18)	10 (23)	1 (4)	3 (27)
LDH, Mean +/ mean −	1818/2395	1818/2395	1801/2599	2077/1652	1959/3346	2839/1727	1573/2484	2972/1746^*	1930/1949	2071/1609	1972/2103	2363/1824	2532/2020	1411/2180	1923/2116	2167/2236	2639/1357
Karyotype, n = positive patients (%)
Good	22 (100)	21 (95)^†	22 (100)^†	21 (95)	22 (100)	10 (45)	15 (68)	5 (23)	3 (16)	9 (41)^†	0 (0)^†	5 (23)	1 (5)	13 (59)^†	1 (5)	0 (0)	0 (0)^†
Intermediate^‡	93 (82)	64 (57)^†	87 (77)^†	104 (92)	105 (93)	49 (43)	85 (75)	26 (23)	20 (22)	79 (70)^†	1 (1)^†	47 (42)	12 (11)	7 (6)^†	23 (20)	4 (7)	5 (17)^†
Poor	28 (87)	26 (81)^†	14 (44)^†	26 (81)	31 (97)	8 (25)	25 (78)	5 (17)	2 (8)	15 (47)^†	4 (19)^†	12 (38)	3 (9)	6 (19)^†	5 (16)	2 (13)	4 (66)^†
Failure or not done	10 (100)	9 (90)	6 (60)	10 (100)	10 (100)	4 (40)	4 (40)	8 (80)	1 (12)	8 (80)	0 (0)	1 (10)	2 (20)	2 (20)	3 (30)	0 (0)	1 (50)
FAB morphology, n = positive patients (%)
M0	4 (100)^†	4 (100)^†	2 (50)^†	4 (100)	4 (100)	0 (0)^†	3 (75)^†	0 (0)^†	0 (0)^†	3 (75)^†	1 (25)	1 (25)^†	0 (0)^†	2 (50)^†	2 (50)^†	0 (0)^†	0 (0)
M1	23 (66)^†	25 (71)^†	26 (74)^†	30 (86)	32 (91)	13 (37)^†	24 (69)^†	1 (3)^†	3 (12)^†	15 (43)^†	1 (4)	9 (26)^†	0 (0)^†	3 (9)^†	4 (11)^†	0 (0)^†	0 (0)
M2	54 (86)^†	52 (82)^†	52 (82)^†	58 (92)	62 (98)	15 (24)^†	56 (89)^†	1 (2)^†	3 (5)^†	34 (54)^†	1 (2)	19 (30)^†	0 (0)^†	20 (32)^†	7 (11)^†	0 (0)^†	5 (38)
M4	33 (94)^†	20 (57)^†	31 (88)^†	34 (97)	34 (97)	20 (57)^†	28 (80)^†	18 (51)^†	9 (36)^†	30 (86)^†	2 (8)	17 (49)^†	7 (20)^†	2 (6)^†	15 (43)^†	2 (11)^†	3 (50)
M4E	7 (100)^†	6 (86)^†	7 (100)^†	7 (100)	7 (100)	4 (57)^†	7 (100)^†	4 (57)^†	4 (66)^†	6 (86)^†	0 (0)	2 (29)^†	1 (14)^†	0 (0)^†	0 (0)^†	1 (50)^†	0 (0)
M5	25 (100)^†	5 (20)^†	9 (36)^†	20 (80)	21 (84)	18 (72)^†	4 (16)^†	20 (80)^†	7 (35)^†	23 (92)^†	0 (0)	17 (68)^†	10 (40)^†	1 (4)^†	7 (28)^†	2 (20)^†	2 (29)
M6	7 (100)^†	7 (100)^†	2 (29)^†	7 (100)	7 (100)	1 (14)^†	6 (86)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)
M7	1 (100)^†	1 (100)^†	0 (0)^†	1 (100)	1 (100)	0 (0)^†	1 (100)^†	0 (0)^†	ND	0 (0)^†	ND	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	1 (100)^†	ND
Pgp expression, Mean +/ mean −	.27/.29	.27/.30	.26/.30	.27/.38^*	.28/.31	.31/.26	.31/.30	.29/.27	.25/.29	.26/.28	.3/.27	.32/.25	.30/.28		.27/.27	.15/.27	.20/.24
Pgp activity, Mean +/ mean −	.47/.45	.55/.3^*	.49/.42	.45/.64^*	.48/.31	.36/.54^*	.51/.36	.32/.5^*	.33/.5	.41/.51	.3/.46	.4/.5	.25/.49^*	.55/.46	.36/.5^*	.4/.5	.37/.47

	HLA-DR	CD34	MPO	CD33	CD13	CDw65	CD117	CD14	CD2	CD4	CD5	CD7	CD10	CD19	TdT	CD41	CD56
Patients, N	177	177	177	177	177	177	177	177	142	177	130	177	177	177	177	99	42
Positive patients, n (%)	154 (87)	120 (68)	129 (73)	161 (91)	168 (95)	71 (40)	129 (73)	44 (25)	26 (18)	111 (63)	5 (4)	65 (37)	18 (10)	28 (16)	32 (18)	6 (6)	10 (24)
Age, y, Mean +/ mean −	54/62	54/56	53/58	54/60	55/43	53/58	58/61	53/54	58/54	55/54	ND	49/58	59/53	49/55^*	62/53^*	48/53	50/57
WBC at diagnosis, Mean +/ mean −	54/79	45/75^*	59/57	61/8^*	55/85	59/58	42/48	88/46^*	53/54	58/48	90/54	76/42^*	75/54	45/58	39/58	100/59	40/43
WHO PS, n (%)
<2	116 (87)	85 (64)	100 (75)	122 (92)	126 (95)	54 (41)	104 (78)^†	31 (23)	20 (18)	82 (62)	4 (4)	50 (38)	13 (10)	20 (15)	22 (16)	5 (7)	7 (22)
≥2	38 (86)	35 (79)	29 (66)	39 (89)	42 (95)	17 (39)	25 (57)^†	13 (29)	6 (19)	29 (66)	1 (3)	15 (34)	5 (11)	8 (18)	10 (23)	1 (4)	3 (27)
LDH, Mean +/ mean −	1818/2395	1818/2395	1801/2599	2077/1652	1959/3346	2839/1727	1573/2484	2972/1746^*	1930/1949	2071/1609	1972/2103	2363/1824	2532/2020	1411/2180	1923/2116	2167/2236	2639/1357
Karyotype, n = positive patients (%)
Good	22 (100)	21 (95)^†	22 (100)^†	21 (95)	22 (100)	10 (45)	15 (68)	5 (23)	3 (16)	9 (41)^†	0 (0)^†	5 (23)	1 (5)	13 (59)^†	1 (5)	0 (0)	0 (0)^†
Intermediate^‡	93 (82)	64 (57)^†	87 (77)^†	104 (92)	105 (93)	49 (43)	85 (75)	26 (23)	20 (22)	79 (70)^†	1 (1)^†	47 (42)	12 (11)	7 (6)^†	23 (20)	4 (7)	5 (17)^†
Poor	28 (87)	26 (81)^†	14 (44)^†	26 (81)	31 (97)	8 (25)	25 (78)	5 (17)	2 (8)	15 (47)^†	4 (19)^†	12 (38)	3 (9)	6 (19)^†	5 (16)	2 (13)	4 (66)^†
Failure or not done	10 (100)	9 (90)	6 (60)	10 (100)	10 (100)	4 (40)	4 (40)	8 (80)	1 (12)	8 (80)	0 (0)	1 (10)	2 (20)	2 (20)	3 (30)	0 (0)	1 (50)
FAB morphology, n = positive patients (%)
M0	4 (100)^†	4 (100)^†	2 (50)^†	4 (100)	4 (100)	0 (0)^†	3 (75)^†	0 (0)^†	0 (0)^†	3 (75)^†	1 (25)	1 (25)^†	0 (0)^†	2 (50)^†	2 (50)^†	0 (0)^†	0 (0)
M1	23 (66)^†	25 (71)^†	26 (74)^†	30 (86)	32 (91)	13 (37)^†	24 (69)^†	1 (3)^†	3 (12)^†	15 (43)^†	1 (4)	9 (26)^†	0 (0)^†	3 (9)^†	4 (11)^†	0 (0)^†	0 (0)
M2	54 (86)^†	52 (82)^†	52 (82)^†	58 (92)	62 (98)	15 (24)^†	56 (89)^†	1 (2)^†	3 (5)^†	34 (54)^†	1 (2)	19 (30)^†	0 (0)^†	20 (32)^†	7 (11)^†	0 (0)^†	5 (38)
M4	33 (94)^†	20 (57)^†	31 (88)^†	34 (97)	34 (97)	20 (57)^†	28 (80)^†	18 (51)^†	9 (36)^†	30 (86)^†	2 (8)	17 (49)^†	7 (20)^†	2 (6)^†	15 (43)^†	2 (11)^†	3 (50)
M4E	7 (100)^†	6 (86)^†	7 (100)^†	7 (100)	7 (100)	4 (57)^†	7 (100)^†	4 (57)^†	4 (66)^†	6 (86)^†	0 (0)	2 (29)^†	1 (14)^†	0 (0)^†	0 (0)^†	1 (50)^†	0 (0)
M5	25 (100)^†	5 (20)^†	9 (36)^†	20 (80)	21 (84)	18 (72)^†	4 (16)^†	20 (80)^†	7 (35)^†	23 (92)^†	0 (0)	17 (68)^†	10 (40)^†	1 (4)^†	7 (28)^†	2 (20)^†	2 (29)
M6	7 (100)^†	7 (100)^†	2 (29)^†	7 (100)	7 (100)	1 (14)^†	6 (86)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)
M7	1 (100)^†	1 (100)^†	0 (0)^†	1 (100)	1 (100)	0 (0)^†	1 (100)^†	0 (0)^†	ND	0 (0)^†	ND	0 (0)^†	0 (0)^†	0 (0)^†	0 (0)^†	1 (100)^†	ND
Pgp expression, Mean +/ mean −	.27/.29	.27/.30	.26/.30	.27/.38^*	.28/.31	.31/.26	.31/.30	.29/.27	.25/.29	.26/.28	.3/.27	.32/.25	.30/.28		.27/.27	.15/.27	.20/.24
Pgp activity, Mean +/ mean −	.47/.45	.55/.3^*	.49/.42	.45/.64^*	.48/.31	.36/.54^*	.51/.36	.32/.5^*	.33/.5	.41/.51	.3/.46	.4/.5	.25/.49^*	.55/.46	.36/.5^*	.4/.5	.37/.47

Other markers tested included (number of samples tested/% of positive cases): CD3 (30/0%), cCD3 (175/2%), CD8 (20/0%), CD20 (51/0%), CD22 (31/3%), and cCD22 (175/0%). ND indicates not determined. Shaded areas indicate P values no more than .05.

Indicates the Mann-Whitney U test was used; P ≤ .05.

†

Indicates the Fisher exact test was used; P ≤ .05.

‡

This includes a normal karyotype and another intermediate prognostic karyotype.

View Large

This Feature Is Available To Subscribers Only